- Home
- Syfovre
Syfovre
What is Syfovre?
Syfovre is used to treat a form of macular degeneration called geographic atrophy (GA) to help preserve vision by slowing vision loss and, therefore, blindness. Syfovre injection works by slowing the growth of GA lesions by controlling part of the immune system that is overactive. It is given as an injection into the eye (intravitreal injection) every 25 to 60 days.
Syfovre FDA approval was received on February 17, 2023, for the treatment of geographic atrophy secondary to age-related macular degeneration for the company Apellis. Syfovre injection contains the active ingredient pegcetacoplan, which is a complement inhibitor.
Syfovre injection works by controlling part of the immune system called the complement system. In age-related macular degeneration, the complement system is overactive, which may cause damage to the retinal cells and progression of geographic atrophy. Syfovre works (mechanism of action) by binding and inhibiting a protein called C3, which regulates complement overactivation, and this helps slow vision loss.
What is Geographic Atrophy?
Geographic atrophy lesions are damaged areas in the retina caused by age-related macular degeneration. Over time, the geographic atrophy lesion(s) become larger and can spread to the center of the retina (fovea), which is the area most important for sharp vision. The progression of the lesion over the fovea causes vision loss and blindness.
How does Syfovre work?
Syfovre works (mechanism of action) by inhibiting C3, a protein in the complement system, which is part of the immune system. In AMD, the complement system is overactive and is involved in the damage of retinal cells. When Syfovre injection inhibits C3, it controls the complement system, which slows the damage to the retinal cells and the progression of geographic atrophy.
Free Case Review
Get in touch with a legal expert today. The info you provide will remain private, and never be shared without consent.
Get Legal Help
Get In Touch
Call or Text 24/7